What is PI3K?
PI3K (phosphatidylinositol 3-kinase) is a lipid kinase that phosphorylates membrane phosphatidylinositol-4,5-bisphosphate to generate PIP3 — the membrane signal that recruits Akt to the plasma membrane and triggers the activation cascade downstream of receptor engagement.
What the research literature says
PI3K is a family of lipid kinases that catalyse phosphorylation of the 3-hydroxyl on the inositol ring of membrane phosphoinositides. The class IA enzymes — the family most directly relevant to growth-factor signalling — are heterodimers of a catalytic subunit (p110α, p110β, or p110δ) and a regulatory subunit (p85α and related variants). The regulatory subunit carries SH2 domains that dock onto phosphotyrosine residues on activated receptor tyrosine kinases.
Once active, PI3K phosphorylates membrane PIP2 to generate PIP3. PIP3 is a transient membrane lipid that serves as a docking platform for any protein carrying a pleckstrin-homology (PH) domain — including Akt and its upstream activating kinase PDK1. The Hsieh BPC-157 mechanism work establishes PI3K as the upstream lipid-kinase step in the VEGFR2-Akt-eNOS cascade (PMID 27847966), with downstream consequences across the cytoprotection map consolidated in subsequent Sikiric work (PMID 35125818, PMID 38980576).
The detailed coverage of PI3K’s role in peptide-research signalling cascades is in the PI3K glossary entry.
Why this matters in research context
PI3K matters in peptide-research contexts primarily as the upstream lipid-kinase that couples receptor engagement (typically VEGFR2 or other receptor tyrosine kinases) to downstream Akt activation. Researchers studying mechanism arms downstream of receptor engagement — Akt signalling, mTOR activation, eNOS-driven nitric oxide output — should account for PI3K as the critical intermediate step.
Related compounds
- BPC-157 10mg — engages VEGFR2-PI3K-Akt-eNOS cascade
- PI3K (glossary entry) — detailed mechanism reference
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Sikiric P et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances. World J Gastroenterol 2022;28(1):1-22. [PMID 35125818]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.